Page 4 - 68214310 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Omeros (NASDAQ:OMER – Get Rating) and Verve Therapeutics (NASDAQ:VERV – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, earnings, risk, profitability and valuation. Analyst Ratings This is a breakdown of recent recommendations and […]

Omeros Co. (NASDAQ:OMER – Get Rating) has been given an average rating of “Hold” by the eight brokerages that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, three have given a hold rating, one has given a buy rating and one has issued a strong buy rating […]

Zacks Investment Research cut shares of Omeros (NASDAQ:OMER – Get Rating) from a buy rating to a hold rating in a research report report published on Wednesday morning, Zacks.com reports. According to Zacks, “Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central […]

Omeros Co. (NASDAQ:OMER – Get Rating) has received a consensus recommendation of “Hold” from the eight brokerages that are currently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, two have given a hold recommendation, two have assigned a buy recommendation and one has given a strong buy […]

Omeros (NASDAQ:OMER – Get Rating) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing the Zacks’ consensus estimate of $0.91 by ($1.28), Yahoo Finance reports. During the same period in the prior year, the business posted ($0.54) earnings per share. Shares of NASDAQ OMER opened at $6.46 […]